Could one dose beat two? new trial tests simpler treatment for parasitic liver disease
NCT ID NCT06367361
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether one or two doses of the drug oxfendazole can cure chronic fascioliasis (a liver infection caused by a parasite) as well as the standard two-dose treatment with triclabendazole. About 336 adults in Peru will be randomly assigned to one of three groups. Researchers will check for parasite eggs in stool samples 7 and 30 days after treatment to see if the infection is gone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- oxfendazole
- What this could lead to
- If successful, this could provide a simpler, one-dose treatment option for fascioliasis, a parasitic liver infection.
- What could go wrong
- This is a Phase 2 trial with 336 participants, so results are preliminary. The drug may not be as effective as the standard treatment, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 336 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male and female subjects eighteen years or older with positive stool microscopy and/or egg counts confirmed by qualitative and/or quantitative stool microscopy performed within the past 14 days. 2. Subjects capable of understanding the informed consent process and providing written informed consent. 3. Willingness to give informed consent. Exclusion Criteria: 1. Subjects reporting previous treatment for fascioliasis 2. Subjects with a stool egg count \> 300 eggs/g in stool samples 3. Women with a positive urine pregnancy test or planning to become pregnant 4. Women that are nursing 5. Alanine aminotransferase (ALT) ≥ 3 or Aspartate aminotransferase (AST) ≥ 3 times above the upper limit of normal within 14 days before enrollment. 6. Subjects with active cerebral cysticercosis determined by serology and imaging studies 7. Subjects with known liver disease, liver cirrhosis, or end stage renal disease 8. Subjects with known allergy or AEs to benzimidazole drugs 9. Subjects taking carbamazepine, phenobarbital, phenytoin, or other medication known to decrease the serum concentrations of benzimidazoles. 10. Women unable or unwilling to use an acceptable birth control method. 11. Male volunteers who are unwilling to ensure pregnancy prevention in their partner. 12. Volunteers with a previously recorded electrocardiogram showing heart-rate corrected (QTc) prolongation, or who are taking medications associates with heart-rate corrected (QTc) prolongation, such as selective serotonin reuptake inhibitors, quinolones, or macrolides. 13. Volunteers with acute fascioliasis. 14. Volunteers who fail to demonstrate adequate understanding of the study after three attempts.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fascioliasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.